Malaria: Difference between revisions

Line 167:

[https://www.sciencedirect.com/science/article/pii/S0264410X15014139 by Nimfa Teneza-Mora ScienceDirect]

Malaria remains an important health threat to non-immune travelers with the explosive growth of global travel. Populations at high risk of acquiring malaria infections include once semi-immune travelers who visit friends and relatives, military forces, business travelers and international tourists with destinations to sub-Saharan Africa, where malaria transmission intensity is high.

=====Two Decades of Commitment to Malaria Vaccine Development: Glaxosmithkline Biologicals=====

[https://www.ncbi.nlm.nih.gov/books/NBK1706/ by W. Ripley Ballou and Conor P. Cahill NIH]

GlaxoSmithKline Biologicals (GSK) is committed to the development of a safe and effective malaria vaccine. Its research program in this field was initiated in 1984 and has been continuously active to this day, making it unparalleled within the vaccine industry. Although it works in partnerships with several leading organizations from the public sector, this effort has required GSK to invest major financial and human resource commitments, and its partners rely heavily on the company’s global infrastructure and expertise in research, advanced clinical development, regulatory, large-scale manufacturing, and commercialization.

Malaria: Difference between revisions

Lilly (talk | contribs)

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 167: / Line 167: @@
 [https://www.sciencedirect.com/science/article/pii/S0264410X15014139 by Nimfa Teneza-Mora  ScienceDirect]
   Malaria remains an important health threat to non-immune travelers with the explosive growth of global travel. Populations at high risk of acquiring malaria infections include once semi-immune travelers who visit friends and relatives, military forces, business travelers and international tourists with destinations to sub-Saharan Africa, where malaria transmission intensity is high.
+=====Two Decades of Commitment to Malaria Vaccine Development: Glaxosmithkline Biologicals=====
+[https://www.ncbi.nlm.nih.gov/books/NBK1706/ by W. Ripley Ballou and Conor P. Cahill NIH]
+ GlaxoSmithKline Biologicals (GSK) is committed to the development of a safe and effective malaria vaccine. Its research program in this field was initiated in 1984 and has been continuously active to this day, making it unparalleled within the vaccine industry. Although it works in partnerships with several leading organizations from the public sector, this effort has required GSK to invest major financial and human resource commitments, and its partners rely heavily on the company’s global infrastructure and expertise in research, advanced clinical development, regulatory, large-scale manufacturing, and commercialization.